News

Who will get cancer treatment-induced cardiotoxicity?


 

AT THE HFSA ANNUAL SCIENTIFIC MEETING

References

“There is a real opportunity here to improve the care of cancer patients and prevent heart failure,” Dr. Lenihan concluded.

He reported receiving research support from Singulex, Millenium, and Acorda as well as serving as a consultant to Onyx and Roche.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

CardioMEMS heralds new proactive era in heart failure management
MDedge Internal Medicine
Heart failure readmission cuts may be a phone call away
MDedge Internal Medicine
Heart failure hospitalizations jump after major holidays
MDedge Internal Medicine
Hospitalists shine in study of heart failure outcomes
MDedge Internal Medicine
Advanced practice registered nurses in cardiology
MDedge Internal Medicine
Androgen-deprivation therapy linked to cardiac death
MDedge Internal Medicine
Four lifestyle changes might prevent 40% of heart failure
MDedge Internal Medicine
Vagal stimulation advances for heart failure
MDedge Internal Medicine
Annual echo an option for cardiac allograft vasculopathy screening
MDedge Internal Medicine
Cancer treatment–induced cardiotoxicity greatly underappreciated
MDedge Internal Medicine